Clinical Trials Directory

Trials / Completed

CompletedNCT01916226

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
682 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs. cetirizine on allergic nasal and ocular symptoms and quality of life in adult subjects with SAR. It is hypothesized that FPNS provides greater nasal symptom relief than cetirizine. The primary measure used to test this hypothesis is the change from baseline over two weeks in reflective total nasal symptom score (rTNSS) compared between FPNS and cetirizine. Approximately 648 subjects will be randomized into a 1:1:1:1 ratio of treatment allocation across approximately twenty-five to thirty-five sites in the US during the 2013 fall allergy season. All subjects will be outpatients. The total duration of study will be approximately 21 days including 7 days of screening period, and 14 days of treatment period.

Conditions

Interventions

TypeNameDescription
DRUGFPNSBottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
DRUGFPNS PlaceboBottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
DRUGCetirizineOver-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
DRUGCetirizine PlaceboOver-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).

Timeline

Start date
2013-08-01
Primary completion
2013-10-01
Completion
2013-10-17
First posted
2013-08-05
Last updated
2018-06-20
Results posted
2014-08-27

Locations

31 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01916226. Inclusion in this directory is not an endorsement.